歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > MAPK > Talmapimod

瀏覽歷史

S84867

Talmapimod

源葉(MedMol) 98%
  • 英文名:
  • Talmapimod
  • 別名:
  • CAS號(hào):
  • 309913-83-5
  • 分子式:
  • C27H30ClFN4O3
  • 分子量:
  • 513
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S84867-5mg 98% ¥990.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S84867-10mg 98% ¥1720.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S84867-25mg 98% ¥3600.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S84867-50mg 98% ¥5200.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(shū)(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說(shuō)明書(shū)。
  • 產(chǎn)品描述: Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs
  • 靶點(diǎn): p38α:9 nM (IC50);p38β:90 nM (IC50);p38MAPK
  • 體內(nèi)研究:
    Targeting p38α MAPK with Talmapimod (SCIO-469) decreases myeloma burden in addition to preventing the development of myeloma bone disease. Talmapimod inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models. Talmapimod (10-90 mg/kg; p.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination Animal Model: Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors) Dosage: P.o.; twice daily orally for 14 days Administration: 10, 30, 90 mg/kg Result: Dose-dependently reduced tumor growth.
  • 參考文獻(xiàn):
    1. Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23(54), 8766-76. 2. Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49(10):1963-75. 3. Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease,reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67(10):4572-7. 4. Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: 2-8℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 1.949 ml 9.747 ml 19.493 ml
    5 mM 0.39 ml 1.949 ml 3.899 ml
    10 mM 0.195 ml 0.975 ml 1.949 ml
    50 mM 0.039 ml 0.195 ml 0.39 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。